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Introduction 
The typical thickness of the retina in people with healthy eyes is 200 lm, which can vary slightly 
according to the part of the retina measured and type of ocular coherence tomography (OCT) used, 
with separate studies having reported either no change or a small decrease in thickness with increasing 
age1,2. Damage to the eye caused by conditions such as macular edema or trauma can lead to 
abnormal fluid accumulation, resulting in thickening of the retina. Along with other microvascular 
changes, thickening of the retina follows sustained periods of hyperglycemia in people with diabetes. 
Although macular edema does not always result in a deterioration in vision, disruption of the fovea can 
cause severe visual impairment1. 
 
The fluocinolone acetonide (FAc) 190 mg intravitreal implant was evaluated in the Fluocinolone 
Acetonide in Diabetic Macular Edema (FAME) study program3,4. Continuous daily release of low levels 
of FAc from the implant has been found to result in a reduction in foveal thickness and edema for up 
to 3 years4. 
 
Historically, laser photocoagulation was considered to be the treatment of choice for DME, due to 
favorable results from the Early Treatment Diabetic Retinopathy Study (ETDRS)5. The FAME study, 
therefore, evaluated FAc intravitreal implant in people with an inadequate response to retinal laser 
therapy. However, since the FAME study was conducted, several landmark trials have demonstrated 
that anti-vascular endothelial growth factor (anti-VEGF) therapy can lead to a significant improvement 
in vision in people with DME6–9, and anti-VEGF therapy is now generally considered to be the first-line 
therapy for this condition. Therefore, in Europe, FAc intravitreal implant is presently indicated for the 
management of chronic DME only where an insufficient response has been achieved with first-line anti-
VEGF therapy. The aim of the ILUVIEN Clinical Evidence Study in the UK (ICE-UK) was to assess the 
effectiveness of FAc intravitreal implant for DME in real world clinical practice. The purpose of this 
study was specifically to evaluate retinal thickness 12 months before and after treatment with the FAc 
190 mg intravitreal implant. 
Methods 
Data source 
The dataset and study methodology have been described in detail elsewhere10. Briefly, for this 
retrospective, multi-center,hospital-based study, data were extracted from medical records for a 
representative cohort of people treated at 13 participating hospitals in the UK and combined into a 
single dataset for the purpose of analysis. Data were generated from retrospective case reviews, 
pseudonymized, and entered into an online data entry tool. The following data were collected at several 
time points within a pre-specified period: patient demographics, medical history, implant data, and data 
from multi-disciplinary and medication reviews. 
Ethical approval 
The lead clinician and Caldicott Guardian at each center gave written approval for extraction of 
anonymized data. The study protocol was approved by the head of research governance at the lead 
clinical center. This study was conducted in accordance with the Declaration of Helsinki and the UK 
Data Protection Act. 
Subjects 
Subjects were people with type 1 or type 2 diabetes treated with FAc 190 mg intravitreal implant for 
DME in at least one eye at a participating site as part of their routine care between April 1, 2013 and 
April 15, 2015. A requirement was a minimum of 12 months’ history prior to implant. Those with a 
history of taking part in any other interventional study for DME or who were lost to follow-up were 
excluded. The index date was defined as the date of first recorded FAc intravitreal implant into the 
study eye. The follow-up period was defined as 12 months post-implant and subjects who received 
FAc intravitreal implant in both eyes were allowed to contribute both eyes to the study. 
Outcomes 
The following clinical outcomes were investigated at 3, 6, and 12 months post-index date: changes in 
central foveal thickness (CFT) and central subfield thickness (CST) and the proportion of treated eyes 
that demonstrated a 10%, 25%, and 50% improvement in CFT or CST. The distribution of CFT and 
CST from 12 months prior to and 12 months postimplant was also investigated. Due to the 
observational nature of this study, there was no restriction on the OCT machine type used to measure 
retinal thickness. 
Subgroups 
Results are presented overall and for two subgroups, based on higher and lower CFT at implant (400 
mm and <400 mm, respectively). Eyes with no recorded CFT measurement at baseline were excluded 
from the subgroup analyses. 
Statistical analysis 
Changes in retinal thickness were compared between implant and the 3-, 6-, and 12-month time points 
using the non-parametric Wilcoxon signed ranks test. The proportion of people achieving a reduction 
in retinal thickness between implant at these time points was compared between subgroups using 
Fisher’s exact test. The proportion of people achieving a target retinal thickness was compared 
between implant and the 3-, 6-, and 12-month time points using McNemar’s test. Last observation 
carried forward was implemented to impute missing values in two stages: on or before index date and 
after index date11. 
 
Mean and median CFT and CST were calculated on a daily basis for the 12 months before and after 
FAc implant. In order to smooth the data, missing values for each day of this 24-month period were 
imputed using linear interpolation11. As linear interpolation could not be used before the first recorded 
value or after the last recorded value, nearest observation carried forward and backwards was used to 
impute the remaining missing values. In order to investigate whether CFTs <200 mm have a detrimental 
effect on vision, visual acuity (ETDRS letter score) in the 12 months prior to and post FAc implant was 
investigated for study eyes with a CFT of <200 mm at baseline using the same methodology. 
 
  
The strength and direction of the association between pairs of visual acuity and CFT measurements 
recorded at FAc implant, 12 months post-FAc implant and at any time in the 12 months prior to and 
post-FAc implantation were measured using the Pearson’s correlation coefficient. Statistical analyses 
were carried out using IBM SPSS Statistics version 20. 
Results 
Data were collected on 311 people, of whom 208 people contributing data from 233 eyes treated with 
FAc intravitreal implant (study eyes) were eligible for inclusion in the study cohort. An attrition flow 
diagram has been previously presented10. Of the 233 study eyes, 208 were first eyes treated with the 
implant, and 25 were a second treatment in the subject’s other eye. 
Patient demographics 
Of the 208 people treated with FAc intravitreal implant in any eye, 128 (62%) were male. The mean 
age was 68.1 years; 176 (85%) had type 2 diabetes (Table 1). Median (interquartile range, IQR) 
duration of diabetes was 18 (11–27) years. Sixty-three eyes (27%) had a CFT of <400 mm at the time 
of implant, and 128 (55%) eyes had a CFT of 400 mm at the time of implant. Forty-two study eyes had 
no recorded CFT measurement within the 12-month period prior to implant, and were, therefore, 
excluded from the subgroup analysis. 
 
Two hundred and seven treated eyes (89%) had a pseudophakic lens at the time of implant. Median 
(IQR) visual acuity at implant was 0.66 (0.48–1.00) LogMAR units (equivalent to median ¼ 52, IQR ¼ 
35–61, ETDRS letters). Mean (SD) CFT at implant was 482 lm (186 lm). Median (IQR) CST at the time 
of implant was 447 (352–587) mm. Median (IQR) numbers of macular laser treatments, steroid 
treatments, and anti-VEGF injections prior to index date were 1.0 (0.0–3.0), 0.0 (0.0–1.0), and 5.0 (2.0–
7.0), respectively. 
Table 1. Baseline characteristics overall and by baseline central foveal thickness. 
Parameter  Overall  By CFT at baseline 
 <400 mm 400 mm 
Subjects, n 208  53 (25%) 115 (55%) 
First eyes treated, n (%) 208 (89%) 53 (25%) 115 (55%) 
Second eyes treated, n (%) 25 (11%) 10 (40%) 13 (52%) 
All treated eyes, n (%) 233  63 (27%) 128 (55%) 
Patient characteristics 
Age last clinic visit, mean (SD)a 68.1 (10.7) 68.2 (11.7) 67.7 (9.8) 
Males, n (%) 128 (62%) 36 (59%) 77 (66%) 
Type 2 diabetes, n (%) 176 (85%) 50 (82%) 99 (85%) 
Tablets 76 (43%) 18 (36%) 49 (49%) 
Insulin 43 (24%) 14 (28%) 21 (21%) 
Insulin plus tablets 57 (32%) 18 (36%) 29 (29%) 
Type 1 diabetes, n (%) 32 (15%) 11 (18%) 18 (15%) 
Tablets 0 (0%) 0 (0%) 0 (0%) 
Insulin 28 (88%) 10 (91%) 15 (83%) 
Insulin plus tablets 4 (13%) 1 (9%) 3 (17%) 
Number of years with diabetes, 
median (IQR)a 
18 (11–27) 18 (12–27) 18 (10–
27) 
Eye characteristics 
Pseudophakic lens status, n (%)b 207 (89%) 53 (84%) 113 (88%) 
Visual 
acuity n 
(%) 224 (96%) 63 (100%) 128 (100%) 
Median (IQR), LogMAR units 0.66 (0.48–1) 0.6 (0.3–0.8) 0.7 (0.5–1) 
Visual 
acuity n 
(%) 224 (96%) 63 (100%) 128 (100%) 
Median (IQR), ETDRS letters 52 (35–61) 55 (45–70) 50 (35–
60) 
CST 
n 
(%) 198 (85%) 58 
   
Median (IQR), lm 447 (352–587) 324 (281–371) 520 (438–
627) 
CFT 
n 
(%) 191 (82%) 63 (100%) 128 (100%) 
mean (SD), lm 482 (186) 285 (77) 579 (141) 
IOP 
n 
(%) 185 (79%) 51 (81%) 102 (80%) 
Median (IQR), mmHg 15 (13–18) 16 (13–18) 15 (12–
17) 
Prior macular laser 
treatments n (%) 146 (63%) 41 (65%) 81 (63%) 
Median (IQR) 1 (0–3) 1 (0–0) 1 (0–3) 
Prior anti-VEGF 
injections n (%) 191 (82%) 50 (79%) 107 (84%) 
Median (IQR) 5 (2–7) 4 (2–7) 5 (2–7) 
Prior ranibizumab 
injections n (%) 162 (70%) 44 (70%) 97 (76%) 
Median (IQR) 3 (0–6) 3 (0–6) 4 (1–6) 
Prior aflibercept 
injections n (%) 1 (0%) 1 (2%) 0 (0%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior bevacizumab 
injections n (%) 74 (32%) 17 (27%) 29 (23%) 
Median (IQR) 0 (0–2) 0 (0–1) 0 (0–0) 
Prior steroid 
injections n 
(%) 101 (43%) 27 (43%) 54 (42%) 
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 
Prior dexamethasone 
injections n (%) 17 (7%) 2 (3%) 4 (3%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior triamcinolone 
injections n (%) 88 (38%) 25 (40%) 51 (40%) 
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 
IOP-lowering medication, n (%) 44 (19%) 12 (19%) 24 (19%) 
Prostaglandin analogs, n (%) 26 (11%) 6 (10%) 15 (12%) 
Beta blockers, n (%) 17 (7%) 4 (6%) 11 (9%) 
Alpha agonists, n (%) 5 (2%) 2 (3%) 3 (2%) 
Carbonic anhydrase inhibitors, n (%) 11 (5%) 0 (0%) 7 (5%) 
Other, n (%) 8 (3%) 3 (5%) 5 (4%) 
  
CFT, central foveal thickness; SD, standard deviation; IQR, interquartile range; LogMAR, Logarithm of the Minimum Angle 
of Resolution; ETDRS, Early Treatment Diabetic Retinopathy Study; CST, central subfield thickness; IOP, intraocular 
pressure; VEGF, vascular endothelial growth factor. 
a These are estimates, as it was not possible to determine the exact date on which these parameters were recorded in 
the dataset. 
bInclude operations carried out on day of implant (n ¼ 18). 
Although some of the characteristics relate to the individual and not the eye, each eye was analyzed as an independent 
observation.  
 
Table 2.  
 
Change in central foveal thickness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CFT, central foveal thickness; IQR, interquartile range. 
 
Central foveal thickness 
Not all subjects had relevant observations at all time points. Following multiple imputation of 
missing values and reporting only paired observations, the median (IQR) CFT decreased following 
3 months             
Overall 
CFT 
subgroup 
148 472 (365–
616) 
355 (254–
474) 
<.001 76 (51%) 61 (41%) 21 (14%) 
<400 mm 47 302 (244–
362) 
282 (211–
343) 
.453 14 (30%) 9 (19%) 1 (2%) 
400 
mm 6 
months 
101 530 (462–
662) 
398 (273–
515) 
<.001 62 (61%) 52 (51%) 20 (20%) 
Overall 
CFT 
subgroup 
169 464 (362–
605) 
331 (239–
462) 
<.001 96 (57%) 75 (44%) 30 (18%) 
<400 mm 56 302 (233–
358) 
279 (210–
357.5) 
.718 18 (32%) 11 (20%) 0 (0%) 
400 mm 
12 
months 
113 531 (464–
674) 
388 (259–
501) 
<.001 78 (69%) 64 (57%) 30 (27%) 
Overall 
CFT 
subgroup 
173 462 (354–
603) 
309 (222–
433) 
<.001 113 (65%) 87 (50%) 37 (21%) 
<400 mm 58 302 (222–
354) 
245 (202–
357) 
.353 23 (40%) 14 (24%) 0 (0%) 
400 mm 115 531 (462–
674) 
349 (245–
467) 
<.001 90 (78%) 73 (63%) 37 (32%) 
             
 
 
   
 
 
   
 
   
implant at each time point: 472 mm (365–616 mm) at implant to 355 mm (254–474 mm) at 3 
months (p < .001), 464 mm (362–605 mm) at implant to 331 mm (239–462 mm) at 6 months (p < 
.001), and 462 mm (354–603 mm) at implant to 309 mm (222–433 mm) at 12 months (p < .001; 
Table 2). 
 
A reduction of 10% in CFT from implant was observed in 76 (51%), 96 (57%), and 113 (65%) 
treated eyes at 3 months, 6 months, and 12 months post-implant, respectively. A reduction of 25% 
and 50% in CFT from implant was observed in 61 (41%) and 21 (14%) treated eyes at 3 months, 
75 (44%) and 30 (18%) at 6 months, and 87 (50%) and 37 (21%) at 12 months, respectively. When 
compared with eyes with a CFT of <400 mm at the time of implant, eyes with a CFT of 400 mm at 
implant were significantly more likely to achieve a reduction in CFT of 25% and 50% at 3 months 
(p < .001, p < 0.001, and p ¼ .004, respectively), 6 months (all p < .001), and 12 months (all p < 
.001). 
 
Mean CFT was higher in the 12 months prior to implant compared with the 12 months after implant, 
and tended to increase in the 3 months immediately prior to implant (Figure 1(a)). CFT continued 
to gradually decrease throughout the 12 months following implant. 
 
When compared with baseline, a steeper cumulative frequency curve was observed at 12 months 
follow-up, with more study eyes achieving lower CFTs at 12 months following FAc implant (Figure 
2). However, the proportion of study eyes with a CFT of 150 mm was the same prior to and 12 
months post-FAc implant (2%). The distribution of study eyes by CFT category of <200 mm, 200 
and <300 mm, 300 and <400 mm, and 400 mm at FAc implant and 12 months postFAc implant is 
described in Figures 3(a and b). Most study eyes had a CFT of 400 mm at the time of FAc 
implantation (66%). At 12 months post-FAc implant, 51% of study eyes moved to a lower CFT 
category, 7% moved to a higher CFT category, and 42% remained in the same category. CFT was 
<300 mm in 16% of eyes at implant and 47% of eyes at 12 months post-implant (p < .001, Figure 
2). For eyes with a CFT <400 mm at the time of implant, CFT was <300 mm in 47% of eyes at the 
time of FAc implant and 66% of eyes at 12 months (p ¼ .382). In those eyes with a CFT of 400 
mm at the time of FAc implant, 38% achieved a CFT of <300 mm at 12 months post-implant. 
Following FAc implant, 6% of eyes had a CFT of <200 mm at the time of FAc implant and 19% of 
eyes had a CFT of <200 mm at 12 months (p < .001). Changes in visual acuity in the 12 months 
prior to and postFAc implant are detailed in Figure 4 for these study eyes. For study eyes with a 
CFT of <200 mm at FAc implant, visual acuity was slightly higher in the 12 months post-FAc 
implant than in the 12 months prior to FAc implant. Comparing the 12 months prior to and post-
FAc implant, a larger improvement in visual acuity was observed in study eyes with a CFT of >200 
mm at FAc implant and a CFT of <200 mm at 
12 months post-FAc implant. 
 
At FAc implantation, a Heidelberg SPECTRALIS OCT machine was used to measure retinal 
thickness in 61% of eyes with a recorded CFT; Topcon 3D OCT-2000 was used in 38% of eyes; 
and Topcon 3D OCT-1000 was used in 1% of eyes. The corresponding values were 56%, 41%, 
and 3%, respectively, at 3 months; 58%, 38%, and 3%, respectively, at 6 months; and 59%, 38%, 
  
and 3%, respectively, at 12 months. Retinal thickness was measured using different OCT machine 
types at baseline and at 3, 6, and 12 months post-FAc implant in 5%, 7%, and 7% of eyes, 
respectively. In study eyes whose CFT was measured using a Heidelberg SPECTRALIS machine 
both prior to FAc implant and 12 months following implant, median CFT decreased from 492 mm 
(IQR ¼ 388–647 mm) to 302 mm (210–421 mm, n ¼ 99). In study eyes where a Topcon 3D OCT-
2000 was used both at baseline and 12 months follow-up, median CFT decreased from 413 mm 
(IQR ¼ 323–514 mm) to 317 mm (293–436 mm, n ¼ 62). 
Correlation between central foveal thickness and visual acuity 
There was a statistically significant negative correlation between visual acuity (ETDRS letter score) 
and CFT at FAc 
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Figure 1. Change in (a) central foveal thickness and (b) central subfield thickness 12 months 
before and after fluocinolone intravitreal implant. Linear interpolation was used to impute missing 
values between CFT and CST scores. Nearest observation carried forward and backwards was 
then used to impute missing values prior to the first and after the last recorded measurement. 
Imputation was carried out in two parts, day –365 to day 0 and day 1 to 365. Individuals with no 
measurement prior to and post-implant were excluded (n ¼ 60 for (a) and n ¼ 52 for (b)). 
 
Figure 2. Cumulative frequency for central foveal thickness recorded at baseline and 12 months 
post-FAc implant. 
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implantation (Pearson’s correlation coefficient r ¼ –0.311, p < .001) and at 12 months post-FAc 
implant (r ¼ –0.250, p < .001, Figures 5(a and b)). A statistically significant negative correlation 
between visual acuity and CFT was also observed when all pairs of CFT measurements and visual 
acuity measurements recorded between 12 months prior to FAc implant and 12 months post-FAc 
implant were analyzed (r ¼ –0.259, p < .001, Figure 5(c)). However, the variance in visual acuity 
accounted for by CFT was small (coefficient of determination, R2 ¼ 0.097 at FAc implant, R2 ¼ 
0.067 at 12 months post-FAc implant and R2 ¼ 0.067 for all measurements in the 12 months prior 
to and post-FAc implant). Change in CFT and change in visual acuity between FAc implant and 
12 months post-FAc implant were also significantly related (r ¼ –0.285, p < .001, R2 ¼ 0.094, 
Figure 5(d)). 
Central subfield thickness 
Median (IQR) CST decreased from baseline at each time point: 448 mm (354–587) at baseline to 
356 mm (276–453 mm) at 3 months (p < .001), 448 mm (359–581 mm) at baseline to 337 mm 
(268–445 mm) at 6 months (p < .001), and 446 mm (359–569 mm) at baseline to 318 mm (262–
419 mm) at 12 months (p < .001, Table 3). 
 
A reduction of 10% in CST was observed in 83 (54%), 103 (58%), and 118 (65%) treated eyes at 
3 months, 6 months, and 12 months post-implant. A reduction of 25% and 50% in CFT from implant 
was observed in 47 (30%) and 13 (8%) treated eyes at 3 months, 62 (35%) and 23 (13%) at 6 
months, and 76 (42%) and 25 (14%) at 12 months, respectively. 
 
Following linear interpolation of missing values (with nearest observation carried forward and 
backwards to impute missing values before the first recorded measurement and after the last 
recorded measurement), mean CST was higher in the 12 months prior to implant than in the 12 
months post-implant (Figure 1(b)). An increase in mean CST was observed in the 4 months prior 
to implant. CST continued to decrease gradually throughout the 12-month period following implant. 
Discussion 
In the 12 months prior to the insertion of the FAc intravitreal implant, central retinal thickness 
continued to increase. Following implant, there was a marked reduction in the central retinal 
thickness. The onset of the beneficial changes in the morphology of the retina appeared to be both 
rapid and sustained for the period of this study. Response was based on CFT prior to treatment 
with the FAc intravitreal implant, being greater in those with a higher CFT (400 mm) at baseline 
and less in those eyes with a lower CFT (<400 mm) at baseline. 
Several types of OCT machine types were used to measure retinal thicknesses across the 13 
participating ophthalmology centers. Retinal thickness measurements have been shown to vary 
depending on machine type, which is thought to be due to variation in the retinal segmentation 
algorithms12. The same OCT machine in each unit was used to measure retinal thickness at 
baseline, and the three follow-up time points in most study eyes. 
Whilst bearing in mind that retinal thinning due to cell loss can also be harmful13, in the longer 
term, it has been reported that eyes that improve most in visual acuity have the greatest decrease 
in retinal thickness14. Nevertheless, the association between visual acuity and retinal thickness is 
still poorly understood15,16. In this study, a significant negative association between visual acuity 
(ETDRS letter score) and CFT was observed. However, the variation in visual acuity explained by 
CFT was low. The Diabetic Retinopathy Clinical Research Network has previously investigated 
the relationship between retinal thickness and visual acuity before and 
 
after laser treatment in patients with DME, and a moderate correlation between visual acuity and 
center point thickness was observed (correlation coefficient of 0.52 at baseline and 0.49, 0.36, 
and 0.38 at 3.5, 8, and 12 months post-laser photocoagulation). Furthermore, a correlation 
between change in visual acuity and change in center point thickness was also reported 
(correlation coefficient of 0.44, 0.30, and 0.43 at 3.5, 8, and 12 months post-laser 
photocoagulation)17. However, the researchers also observed considerable variation in visual 
acuity for a particular level of retinal edema17. 
 
What is not a matter of conjecture is that any increase in retinal thickness from the norm represents 
physiological morbidity. Cataract surgery increases retinal thickness18, and recovery in retinal 
thickness varies by the region of the retina19. However, central point thickness has been shown to 
recover relatively quickly following cataract surgery in people pre-treated with the FAc intravitreal 
 
Figure 3. Central foveal thickness (CFT) at baseline and 12 months post-implant. (a) Distribution of FAc treated eyes 
by CFT category at FAc implant and after 12 months follow-up. (b) Distribution of FAc treated eyes achieving a CFT 
of 200 mm, > 200 and 300 mm, > 300 mm and 400 mm, and >400 mm at 12 months post-implant by CFT at time of 
FAc implant. (c) CFT at FAc implant and after 12 months follow-up by CFT category at implant. (d) Change in CFT 
between FAc implant and 12 months follow-up by CFT category at implant. 
  
implant20. Panretinal photocoagulation is reported to increase local inflammation, resulting in 
effects such as localized cytokine release21. In the later stages of diabetic eye diseases, multiple 
treatments are typically used together in complex patterns of treatment to salvage sight. Retinal 
thickness is thought to be an important and objective measure of clinical outcome14. 
 
Anti-VEGF therapy is now considered to be the first-line treatment for DME, and this class of drugs 
has been shown to be effective in reducing retinal thickness6,22–27. The two licensed anti-VEGF 
products for DME available in the UK— ranibizumab and aflibercept—have been recommended 
by NICE for the treatment of DME in eyes with a central retinal thickness 400 mm, since both 
products have been determined to be cost-effective only in those eyes with this central retinal 
thickness28,29. However, the NICE recommendation for FAc intravitreal implant does not include 
any restrictions based on central retinal thickness30. Laser therapy or intravitreal steroids (in eyes 
with a pseudophakic lens) are the only recommended treatment options in eyes with a central 
macular thickness of <400 mm. In this study, we examined changes in CST and CFT in subgroups 
based on baseline CFT of <400 mm and 400 mm. The change in CFT between implant and the 
end of the 12-month observation period was statistically significantly greater in those with a CFT 
of 400 mm at the time of implant, but not in those 
eyes with a CFT of <400 mm. Eyes with a smaller CFT at the time of FAc implant have less 
potential to improve. Sample size was relatively small in the CFT subgroups. 
 
A reduction in retinal thickness post-FAc implant has also been observed in other studies. In the 
FAME study, baseline mean foveal thickness was 451 mm and 461 mm in the sham and low dose 
(0.2 mg/day) groups, respectively4. At 6 months, the mean foveal thickness was 396 mm in the 
sham group and 318 mm in the 0.2 mg/day group4. At 36 months, mean foveal thickness was 309 
 
Figure 4. Visual acuity 12 months prior to and post-FAc implant in study eyes (a) with a central foveal thickness (CFT) 
< 200 mm at FAc implant (n ¼ 12), and (b) CFT 200 mm at FAc implant and <200 mm at 12 months post-FAc implant 
(n ¼ 24). 
  
m and 280 mm, respectively4. Similar results were observed in this study, where median CFT in 
study eyes had decreased from 464 mm at implant to 331 mm at 6 months. By 12 months, median 
CFT was 309 mm. In the largest published observational study to date, ElGhrably et al.31 reported 
a mean reduction in central macular thickness of 126 lm at 12 months following FAc implant. In 
line with the findings from this study, central macular thickness decreased rapidly after implant, 
and this was sustained 
 
 
Figure 5. Correlates between central foveal thickness (CFT) and visual acuity. (a) Visual acuity and CFT at FAc 
implantation. (b) Visual acuity and CFT at 12 months post-FAc implant. (c) All pairs of visual acuity and CFT 
measurements between 12 months prior to and 12 months post-FAc implant. (d) Change in visual acuity and change 
in CFT between FAc implant and 12-month follow-up. r, Pearson’s correlation coefficient, R2, coefficient of 
determination. Only visual acuity and CFT measurements recorded on the same date were included. 
 
 
 
 
 
 
 
 
 
 
 
 for the 12-month follow-up period31. Several other smaller observational studies have investigated 
the change in central retinal thickness following FAc intravitreal implant for DME. In a retrospective 
study conducted by Elaraoud et al.32, central retinal thickness was found to have decreased by a 
mean 
of 149 mm at 3 months post-FAc implant. In this study, 7% of study eyes moved into a higher CFT 
category between baseline and 12 months post-FAc implant. Elaraoud et al.32 also reported a 
worsening in CFT in four out of the 22 eyes included in their retrospective study at 3 months 
postimplant. In a prospective, non-randomized, phase 4, pilot study, Figueira et al.33 observed a 
statistically significant decrease in CST 12 months after FAc implant, and a rapid decrease in CST 
in the first week after implant. Rapid and sustained reductions in CST following FAc implant were 
also observed in a prospective study conducted by Massin et al.34 
 
Strengths and limitations 
The strengths and limitations of the study have been described previously10. As this is an 
observational study, several limitations are likely to apply, including the misclassification of 
outcomes, effectiveness, and safety. Outcomes were not measured at set times post-index, and 
were not consistently available across all participating centers for all the time points. Recall of 
participants to attend measurement may have led to differential misclassification and missing 
values. There were inconsistencies in the information recorded on cataract operations and lens 
status. Duration of DME was not recorded. Analysis was restricted to 12 months follow-up post-
implant, because available follow-up after this date varied from person to person. 
First and second treated eyes from the same person were analyzed as independent observations. 
However, second eyes may be more likely to be treated with FAc intravitreal implant if the patient 
had a positive response to treatment in the first eye. In addition, treatment of the second eye may 
be more likely to occur at certain treatment centers. Whilst minimizing the elimination of individuals 
Table 3. Change in central subfield thickness.
 
 
3 months             
Overall 
CFT 
subgroup 
155 448 (354–587) 356 (276–453) <.001 83 (54%) 47 (30%) 13 (8%) 
<400 mm 43 327 (269–377) 289 (257–343) .015 15 (35%) 5 (12%) 0 (0%) 
400 
mm 6 
months 
99 503 (429–617) 382 (294–472) <.001 61 (62%) 40 (40%) 13 (13%) 
Overall 
CFT 
subgroup 
177 448 (359–581) 337 (268–445) <.001 103 (58%) 62 (35%) 23 (13%) 
<400 mm 51 327 (273–371) 291 (239–344) .012 19 (37%) 6 (12%) 0 (0%) 
400 mm 
12 months 
110 516 (436–622) 368 (274–460) <.001 76 (69%) 53 (48%) 23 (21%) 
Overall 
CFT 
subgroup 
181 446 (359–569) 318 (262–419) <.001 118 (65%) 76 (42%) 25 (14%) 
<400 mm 53 327 (281–371) 274 (251–333) .005 24 (45%) 10 (19%) 0 (0%) 
400 mm 112 516 (436–620) 337 (270–445) <.001 86 (77%) 62 (55%) 25 (22%) 
                                              
 
 
 
 
 
 
 
CFT, central foveal thickness; CST, central subfield thickness; IQR, interquartile range. 
     
   
      
 
 
   
 
 
   
 
 
  
  
from the analysis, methods used to impute missing values have inherent limitations. The last 
observation carried forward can produce a biased estimate of treatment effect. However, as retinal 
thickness continued to improve over the duration of the period of follow-up, we believe that last 
observation carried forward will provide a conservative estimate for the effect of FAc on retinal 
thickness. 
 
Conclusions 
In our cohort of people with DME, where 96% had a prior history of receiving anti-VEGF injections, 
laser therapy, and/or other intravitreal steroids, central retinal thickness increased in the 12 months 
prior to the insertion of the FAc intravitreal implant. Following treatment with the FAc intravitreal 
implant, a marked and sustained reduction in central foveal thickness was observed in the 12 
months following implant. A statistically significant negative correlation between central foveal 
thickness and visual acuity (ETDRS letters score) was also observed. However, the variance in 
visual acuity accounted for by central foveal thickness was low. 
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